Addex Therapeutics (ADXN) Change in Accured Expenses (2020 - 2026)
Addex Therapeutics (ADXN) posted Change in Accured Expenses of -$6.6 billion for Q1 2026, down 444.11% sequentially from -$1.2 billion in Q2 2025, and down 690.89% YoY from $1.1 billion in Q1 2025.
Addex Therapeutics (ADXN) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Addex Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$6.6 billion in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -6.59 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.59 Bn |
| Mar 31, 2026 | -6.59 Bn |
| Jun 30, 2025 | -1.21 Bn |
| Jun 30, 2025 | -1.21 Bn |
| Mar 31, 2025 | 1.12 Bn |
| Mar 31, 2025 | 1.12 Bn |
| Sep 30, 2024 | -33.85 Bn |
| Sep 30, 2024 | -33.85 Bn |
| Jun 30, 2024 | -721.30 Bn |
| Jun 30, 2024 | -721.30 Bn |
| Mar 31, 2024 | 747.32 Bn |
| Mar 31, 2024 | 747.32 Bn |
| Sep 30, 2023 | -5.96 Bn |
| Sep 30, 2023 | -5.96 Bn |
| Jun 30, 2023 | -44.25 Bn |
| Jun 30, 2023 | -44.25 Bn |
| Mar 31, 2023 | -33,127.90 |
| Mar 31, 2023 | -33,127.90 |
| Sep 30, 2022 | -1,660.87 |
| Sep 30, 2022 | -1,660.87 |